CD26: A novel treatment target for T-cell lymphoid malignancies? (Review)

  • Authors:
    • Kazuya Sato
    • Nam H. Dang
  • View Affiliations

  • Published online on: March 1, 2003     https://doi.org/10.3892/ijo.22.3.481
  • Pages: 481-497
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

CD26 is a surface glycoprotein with intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity with multiple biological roles, including being intricately involved in immunoregulation as a T-cell activation molecule and as a regulator of chemokine function. T-cell lymphoid malignancies represent a heterogeneous group of diseases that are generally aggressive and are for the most part resistant to current treatment modalities. Previous studies showed that CD26 is expressed on selected T-cell neoplasms, suggesting a potential role for CD26 in tumor development. We review herein recent classification schemes for T-cell lymphoid malignancies that take into account various facets of their clinical presentation. In addition, we discuss findings supporting the conclusion that CD26 has an essential role in human T-cell activation, as well as its ability to regulate the biological effects of selected chemokines through its DPPIV activity. Finally, we will present recent work from our laboratory that indicates a potential role for CD26 as a molecular target for novel treatment modalities for T-cell lymphoid malignancies.

Related Articles

Journal Cover

March 2003
Volume 22 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sato K and Sato K: CD26: A novel treatment target for T-cell lymphoid malignancies? (Review). Int J Oncol 22: 481-497, 2003
APA
Sato, K., & Sato, K. (2003). CD26: A novel treatment target for T-cell lymphoid malignancies? (Review). International Journal of Oncology, 22, 481-497. https://doi.org/10.3892/ijo.22.3.481
MLA
Sato, K., Dang, N. H."CD26: A novel treatment target for T-cell lymphoid malignancies? (Review)". International Journal of Oncology 22.3 (2003): 481-497.
Chicago
Sato, K., Dang, N. H."CD26: A novel treatment target for T-cell lymphoid malignancies? (Review)". International Journal of Oncology 22, no. 3 (2003): 481-497. https://doi.org/10.3892/ijo.22.3.481